Similar articles

• Antiviral activity and resistance profile of phosphazid--a novel prodrug of AZT.

  Machado J, Salomon H, Oliveira M, Tsoukas C, Krayevsky AA, Wainberg MA. Machado J, et al. Nucleosides Nucleotides. 1999 Apr-May;18(4-5):901-6. doi: 10.1080/15257779908041597. Nucleosides Nucleotides. 1999. PMID: 10432707
• Transmitted human immunodeficiency virus type 1 carrying the D67N or K219Q/E mutation evolves rapidly to zidovudine resistance in vitro and shows a high replicative fitness in the presence of zidovudine.

  García-Lerma JG, MacInnes H, Bennett D, Weinstock H, Heneine W. García-Lerma JG, et al. J Virol. 2004 Jul;78(14):7545-52. doi: 10.1128/JVI.78.14.7545-7552.2004. J Virol. 2004. PMID: 15220429 Free PMC article.
• Selection of mutations in the connection and RNase H domains of human immunodeficiency virus type 1 reverse transcriptase that increase resistance to 3'-azido-3'-dideoxythymidine.

  Brehm JH, Koontz D, Meteer JD, Pathak V, Sluis-Cremer N, Mellors JW. Brehm JH, et al. J Virol. 2007 Aug;81(15):7852-9. doi: 10.1128/JVI.02203-06. Epub 2007 May 16. J Virol. 2007. PMID: 17507476 Free PMC article.
• Quadruple nucleoside therapy with zidovudine, lamivudine, abacavir and tenofovir in the treatment of HIV.

  Stürmer M, Staszewski S, Doerr HW. Stürmer M, et al. Antivir Ther. 2007;12(5):695-703. Antivir Ther. 2007. PMID: 17713153 Review.
• A fossil record of zidovudine resistance in transmitted isolates of HIV-1.

  Kuritzkes DR. Kuritzkes DR. Proc Natl Acad Sci U S A. 2001 Nov 20;98(24):13485-7. doi: 10.1073/pnas.251559398. Proc Natl Acad Sci U S A. 2001. PMID: 11717419 Free PMC article. Review. No abstract available.